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David von Hansemann noticed in 1890 that all of the cancer cells
that he examined were aneuploid and suggested that the aneu-
ploidy might be the cause of the cancer [1]. Based on Hansemann’s
observations and his fundamental discovery that individual chro-
mosomes have different genetic functions, Theodor Boveri ad-
vanced the first genetic cancer theory in 1914: cancer is caused by
the loss of specific growth inhibitory or the gain of specific growth
stimulatory chromosomes [2]. For half a century this remained the
prevailing genetic theory of cancer, despite strong opposition from
Thomas Morgan, who considered that no instances of chromosomal
faults were known to give rise to uncontrolled growth of cells [3].
After the causative agent of Peyton Rous’s chicken sarcoma was dis-
covered to be a retrovirus that inserted an oncogene into the host
genome [4], many cancer researchers discarded the aneuploidy the-
ory, considering the dispute to be resolved in favor of oncogenes
and viruses. Since then the field has been dominated by the view
that cancer is caused by virus-related or virus-unrelated cellular
oncogenes.
The difficulty that many researchers had with the chromosomal or
aneuploidy theory was that no consistent stimulatory or inhibitory
chromosomes could be found in cancers. As a result Boveri’s theory
seemed to be stranded on the same reef that prevented the theory
of continental drift from being accepted by geophysicists, even
though the close fit between Africa and South America had been
obvious to anyone who looked at a world map since sufficiently
accurate maps became available. In the absence of a credible mech-
anism, the hypothesis was rejected by most geophysicists, and the
fact that Alfred Wegener had no recognized expertise in geophysics
doubtless contributed to the skepticism. (Actually, Benjamin Franklin
suggested a plausible mechanism similar to the modern theory of
plate tectonics as long ago as 1782 [5]).
Returning to cancer, there are also serious difficulties with the
oncogene theory. The number of cells in the human body is so
large, and the frequency of random mutations in somatic cells is so
high, that it is certain that any conceivable oncogene, in its sup-
posedly oncogenic state, is already present in every person, but
does not lead to cancer. Such difficulties tend to be brushed aside,
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ond problem with oncogenes is that overexpression of single genes
almost never has any metabolic effects, and under-expression usu-
ally has only minor effects. That is why about 85% of mutations in,
say, yeast, are “silent” [6, 7]: eliminating them from the genome
usually produces no change in phenotype. When “knock-out mice”
first became available [8] it was expected that the function of any
gene could be revealed by observing the effect of eliminating it,
but most such experiments led to disappointment. When a mouse
completely lacks a protein such as myoglobin, which has a well-
understood function in muscles, it can remain healthy, even when
exercised [9].
The almost negligible effects of altering the activities of single genes
can be easily understood in terms of metabolic control analysis, an
approach to metabolic regulation introduced by Henrik Kacser and
Jim Burns in 1973 [10]. Before then, and for considerable time after-
wards, because the new ideas did not become immediately ac-
cepted, it was assumed that each metabolic pathway had a “key
enzyme” or “rate-limiting enzyme”, and that altering the activity of
this enzyme would alter the flux through the pathway in propor-
tion. Kacser and Burns realized, even before many experimental
tests were available, that that could not be correct: flux control is
shared between all of the enzymes in the system, and if the system
is taken to be a whole cell or a whole organism, this means that
most shares must be very small, so that altering a typical enzyme
activity should have little or no effect. When techniques for genetic
manipulation became available, Jürgen Heinisch and colleagues
overexpressed phosphofructokinase (widely regarded as the key
enzyme in fermentation) in yeast by a factor of 3.5, and observed
no effect on the flux to ethanol [11]. This contradicted what was
widely expected, but it was not a surprise for people who had
understood the principles of metabolic control analysis.
The expectation of no effect, however, is the expectation of what
will happen when the activity of a single enzyme is altered. But an-
euploidy alters the activities of many enzymes at a time, and the
analysis is not so simple. Even in Down syndrome, with fewer than
2% of genes affected by trisomy of the smallest chromosome, the
effects are not negligible. Cancer cells are far more aneuploid than
those of Down syndrome patients: for example, colon cancer pro-
duces cells in which many chromosomes are triploid, some are
tetraploid, and some are damaged. This is a vastly larger perturb-
ation than trisomy of one small chromosome, and altering the ac-
tivities of a vast number of enzymes must inevitably create large
metabolic disturbance. Down syndrome illustrates the severe ef-
fects that even a minimal degree of aneuploidy can produce, but
people who believe that changing a single enzyme activity, or a
small number of activities, can lead to cancer need to explain why
Down syndrome patients are as normal as they are when they have
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when David Rasnick and Peter Duesberg, as well as Harvey Bialy, partic-
ipated in a meeting that I organized in 1999 [12]. Since then they have
used modern concepts of metabolic control as the basis for a quantita-
tive analysis of metabolism in cancer tissue. Their theory goes a long
way towards explaining how aneuploidy can be a cause rather than a
consequence of cancer. However, there is no longer a reason to doubt
that an error in mitosis is the primary event that produces aneuploidy,
which eventually leads to cancer. In the first session of the 3rd Confer-
ence on Aneuploidy and Cancer, held in Berkeley, California, in January
2017, David Rasnick presented the current state of the theory and com-
pared it with gene-based theories of cancer [13].
This was followed by a lecture in which Henry Heng argued that the
chaotic reorganization of the genome that accompanies aneuploidy
explains the development of cancer better than a gene- initiated
process, and concluded that the survival and adaptive landscapes
are different in cancer [14]. Mathew Bloomfield examined the rela-
tionships between aneuploidy, karyotypic variability and metastasis,
and argued that the appearance of metastases should be regarded
as a form of speciation [15]. Mark Vincent continued in this spirit,
and discussed why targeted drugs for cancer, with the exception of
chronic myeloid leukemia, which he regarded as atypical, have not
resulted in the expected benefits. For him carcinogenesis is a form of
“de-speciation” rather than speciation [16], but that can be regarded
as a matter of definition rather than anything more fundamental.
Much later in the conference Peter Duesberg described many problems
with gene-based theories, noting, for example, that in contrast to con-
ventional Mendelian genetics no common cancer-specific karyotypes
are known; instead, all cancers have individual karyotypes. He argued
that carcinogenesis is a type of speciation [17].
Without rejecting the role of aneuploidy, Marcelo Aldaz argued
against a Manichean approach to cancer, retaining a role for onco-
genes [18]. David Gisselsson described how high-risk cancer is genet-
ically dynamic, both in space and in time [19]. Likewise, Floris Foijer
considered that aneuploidy is characteristic of only two out of three
tumors (much less than the 100% that David Rasnick reported), and
emphasized that p53-deficient knockout mice displayed highly repro-
ducible aneuploidy induction [20]. In a later presentation, Rüdiger
Hehlmann discussed the so-called Philadelphia chromosome, which
is regularly associated with a definite form of human leukemia. The
oncogene ABL on chromosome 9 appears to act in a cooperative
process with aneuploidy and development of leukemia. This sort of
observation can help to provide new recommendations for the
management of acute myeloid leukemia [21]. Jonathan Pollack con-
tinued the discussion of this cancer by examining the cryptic genes
harbored by complex karyotypes, and described a new computer-
based analytical tool for integrating data for copy numbers and
gene expression [22].
Thomas Liehr focused on the copy-number variations of chromosomes
with no obvious clinical effects, which have been known for decades but
have assumed greater visibility with the sequencing of the human genome.
He considered that these need more attention in cancer research [23].
The facial cancer that is devastating the population of Tasmanian
devils, the largest carnivorous marsupial, is an interesting example in
which an oncogene must be completely excluded as a possibility, be-
cause it is contagious, as Jennifer Marshall Graves described, and spreads
by biting of an affected animal by a healthy one: the cancer itself is trans-
ferred. Both the host and the cancer karyotypes are highly conserved; in-
deed the cancer karyotypes are all the same. She went on to describe
the pathogenesis and molecular biology of the tumor [24].
Aleksei Stepanenko returned to the theme of genomic instability as
the driving force of cancer, and specifically the adaptation of cancer
cells to drugs and transgenic manipulations, arguing that increased
resistance to drug re-challenge was the only predictable phenotypic
trait observed in all long-term drug-treated tumor cells [25].
Daniela Cimini discussed the view that tetraploidy of the whole
genome of a cell can be the precursor of chromosomal instability
in cancer, though tetraploidal cell clones with normal centrosome
numbers can also occur. She examined the link between aneu-
ploidy and chromosome instability, focusing especially on breast
cancer, in which the spontaneous return to an unbalanced diploidcell is accompanied by errors, with monosomy of some chromo-
somes and damaged fragments of others [26].
Milena Dürrbaum examined the molecular mechanisms underlying
aneuploidy in human cells from the point of view of systems biology.
She and her colleagues found that gene expression affected com-
mon cellular pathways independently of the cell line, type of aneu-
ploidy, and its origin [27].
Daniele Mandrioli described the work of the Ramazzini Institute in
Bologna in showing that aneuploidy offered an evidence-based
marker for environmental health [28]. (He also pointed out that Theo-
dor Boveri’s theory of cancer [2] was in reality a joint project carried
out with his wife, Marcella O’Grady Boveri.)
Rolf Skotheim used computer analysis to study the question of in-
stability of the transcriptome in cancer, with aberrant processing of
RNA, specifically in the context of samples of colorectal cancer from
555 patients. They found enormous variation between samples [29].
Alfred Böcking addressed the question of “active surveillance” of
localized prostate cancers with a view to avoiding the undesirable
side effects that accompany commonly used aggressive therapies,
which may well be unnecessary for a substantial proportion of
patients, especially in the short term [30].
Andrew Fritz described studies of the spatial arrangement of chro-
mosomes in breast cancer samples, which showed that these
arrangements are not random, so that particular “chromosome ter-
ritories” tend to be associated with particular other ones [31].
Sarantis Gagos discussed the effect of induced replication stress
and extreme telomere dysfunction on chromosomal instability and
cancer cell stemness. The results from human cell lines with alter-
native lengthening of telomeres suggested a trend that preserves
monoclonality [32].
Eduardo Torres discussed the role of sphingolipids in modulating the
fitness of aneuploid cells, because in his view studying the cellular
processes affected by aneuploidy can improve our understanding of
its role in tumor biology [33]. He concluded that these lipids have
important roles in the physiological responses to aneuploidy.
As will be evident from the introductory paragraphs in this report, I
am not a great believer in rate-limiting steps in metabolism, and I
am not convinced that progression of cancer is exceptional. How-
ever, Martha Stampfer took a different view, and argued that
immortalization is the rate-limiting step in human carcinogenesis,
observing that efficient transformation of normal human mammary
epithelial cells does not require gross genomic alterations. She
noted that normal cells from small short-lived mammals like mice
do not stringently repress telomerase and lack a significant replica-
tive senescence barrier. In consequence, mouse cells are not an
adequate model for immortalization in human carcinogenesis [34].
Yi-Hong Zhou studied tumor recurrence after therapy, concluding
that tumor heterogeneity could be maintained by missegregation
of tumor-specific chromosomes in response to extracellular envir-
onmental cues [35]. This interpretation is not necessarily incom-
patible with Rasnick’s view that recurrence is inevitable after any
therapy that destroys only 99.9% of cancer cells, leaving millions
(0.1%) to restore a tumor [13], but in any case it is important to
understand how tumor heterogeneity is established and main-
tained. The meeting ended with a presentation by Yi-Hong Zhou’s col-
league Michelle Digman, who discussed how fluorescence lifetime
imaging microscopy could be used to identify glioblastoma subpopula-
tions [36], which should allow understanding of the role of tumor hetero-
geneity in drug resistance.
In summary, the 3rd Conference on Aneuploidy and Cancer offered
a unique opportunity to discuss many aspects of the origin of aneu-
ploidy and its role in producing cancer—mainly human, but also
other organisms such as Tasmanian devils.
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A theory of what goes wrong with metabolism in cancer requires an
adequate theory of what goes right in healthy cells. This needs to be
based on the theories of metabolic control and metabolic regulation.
To a first approximation the rate of an isolated enzyme-catalysed re-
action is proportional to the enzyme concentration, but that is not
necessarily the case for multi-enzyme systems, in which flux control
is shared among all the enzymes, and the concentration of a particu-
lar enzyme can vary substantially with negligible effects on the flux.
For any one enzyme the degree of flux control is defined by a flux
control coefficient, which is normally never unity, and for systems of
many enzymes it is typically immeasurably small. However, this is
theory: does it work in practice? One indication that it is correct
comes from many failures to increase production of economically
valuable metabolic products by overexpressing the enzymes believed
to be rate-limiting. Another is the observation that in a genetic
disease such as phenylketonuria, heterozygotes with half of the nor-
mal amount of enzyme have no symptoms and are just as healthy as
normal homozygotes. Likewise, inheritance of eye colour in humans
is explained by the fact that eyes with only half the activity of the en-
zymes needed to produce brown eyes are barely different from the
eyes of brown-eyed homozygotes. These examples involve very small
numbers of genes, but in chromosomal disturbances that affect
many genes, such as Down syndrome or more severe cases of
Molecular Cytogenetics 2017, 10(Suppl 2):21 Page 80 of 94aneuploidy, a large number of effects that would be negligible when
considered individually, can add up to very large effects.
The theory of metabolic control needs to be supplemented, however,
with a theory of metabolic regulation, to explain why unregulated
natural systems are very different in behaviour from living systems or
systems designed by engineers. A lake will typically have many
sources of water, but a maximum of one exit, whereas engineered
and living systems allow regulated flow in different directions. A
healthy metabolic system has regulated flows at many different
points, and allows forward and reverse transformations between, for
example, fructose 6-phosphate and fructose 1,6- bisphosphate, to be
possible in the same cells with negligible loss of ATP by hydrolysis.
In this example regulation is achieved by strong inhibition and
activation of phosphofructokinase and fructose bisphosphatase, to
ensure that both processes are not simultaneously in operation. The
underlying principle of metabolic regulation by feedback effects is
that fluxes are determined primarily by the demand for end-products
and as little as possible by the supply of starting materials. If the
necessary regulatory interactions are impaired, as they may be in can-
cer and other illnesses, satisfactory metabolism becomes impossible.
Further reading
1. Kacser H, Burns JA, Fell DA. The control of flux. Biochemical Society
Transactions 1995;23, 341-366. (revised version of the 1973 paper)
2. Cornish-Bowden A. Fundamentals of Enzyme Kinetics (4th edition):
Wiley-VCH, Weinheim; 2012. Chapter 13.
3. Cornish-Bowden A. (2016) Biochemical Evolution: the Pursuit of
Perfection (2nd edition): Garland Science, New York; 2012. Chapter 8.A2
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Gene mutation theory in decline
In 2002, Robert Weinberg admitted that, “For those who believe in
the simplification and rationalization of the cancer process, the actual
course of research on the molecular basis of cancer has been largely
disappointing. Rather than revealing a small number of genetic and
biochemical determinants operating within cancer cells, molecular
analyses of human cancers have revealed a bewilderingly complex
array of such factors [1].” In 2014, he added, “Moreover, even within
a given type of cancer…there were no uniform successions of
genetic change. Instead, each tumor seemed to represent a unique
experiment of nature, acquiring a unique set of mutant genes and in
an unpredictable chronological order.” Weinberg concluded, “The
coupling between observational data and biological insight is frayed
if not broken [2].” November 2016, Bert Vogelstein dealt the muta-
tion theory another blow when he reported that the search for can-
cer causing genes is “hindered by the lack of a gold standard, that is,
bona fide driver gene mutations [3].” It was actually a double blow
since driver genes include oncogenes and tumor suppressor genes.
Theory of chromosomal imbalance
In contrast to “bona fide driver gene mutations,” which are exceedingly
difficult to find, aneuploidy is abundant in cancer cells [4]. Chromo-
somal imbalance is orders of magnitude more powerful than gene
mutations in producing cancer phenotypes [5]. The phenotypes of can-
cer cells are determined by the fraction of the genome out of balance
relative to the euploid cell [6]. Aneuploid cancer cells have substantially
greater amounts of DNA, RNA and protein than normal cells [7]. A 40%
increase in cellular protein produces a 32-fold elevation in membrane
proteins. A 20% increase in cellular protein causes a 30-fold elevation in
secreted proteins [8]. Thus the tumor-associated antigens and the high
levels of secreted proteins responsible for invasiveness and loss of
contact inhibition are the natural consequence of the excess pro-
duction of protein in cancer cells. The additional ATP required for
the synthesis of the extra protein is produced by the aerobic fer-
mentation of glucose [9-11], the so-called Warburg effect.Chromosomal imbalance disrupts the mitotic machinery leading to
the chaotic separation of chromosomes. “The relationship between
aneuploidy and chromosomal instability can be envisioned as a ‘vicious
cycle,’ where one potentiates the other [12].” An extra copy of a single
chromosome is sufficient to produce chromosomal instability [13]. The
greater the imbalance of chromosomes, the greater is the instability
[6, 14]. The survival advantage of cells that gained chromosomes,
coupled with chromosomal instability, leads to the autocatalyzed
progression of aneuploidy during cell division [6, 15, 16].
Much sought-after mechanism of carcinogenesis
Carcinogen-initiated chromosomal imbalance, coupled with the
autocatalyzed progression of aneuploidy during cell division, is ne-
cessary and sufficient to generate cancer on the rare occasions the
cells survive—independent of gene mutation.
Practical utility
The theory of chromosomal imbalance has a number of practical appli-
cations [17]. Monitoring aneuploidy is the most accurate and sensitive
way of detecting cancer and following its progression [18]. Reducing
exposure to aneuploidogens is the best way to reduce the incidence of
cancer. Aneuploidy damages a cell and is the reason primary cancer
cells tend to die at high rates in vivo and in culture [19, 20]. Indeed, the
lability inherent in aneuploid cells is the likely reason for the spontan-
eous remission of all types of cancer. The theory of chromosomal im-
balance predicts that a variety of non-toxic perturbations of the host
(such as induced fever) may therapeutically nudge the tumor out of its
stable, comfortable environment, increasing the natural spontaneous
death rate of the cancer cells [17].
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Background: Current cancer evolutionary research has been framed
by the Gene Mutation Theory and by Neo-Darwinia stepwise evolu-
tion. Conventional wisdom includes: 1) cancer is a genetic disease
caused by common cancer gene mutations; 2) cancer development
follows the process of the accumulation of small genetic changes
over time, or clonal evolution; and 3) precision genetic profiling is
the key for diagnosis/molecular targeting. Those concepts, however,
are challenged by sequencing data and the two phases of cancer
evolution (punctuated phase where drastic karyotype changes dom-
inate and stepwise phase where gene mutation and epigenetic alter-
ation dominate). Furthermore, the cytogenetic description of
genome chaos, the rapid and massive genome re-organization under
stress, and its recent confirmation by cancer genome sequencing call
for the search for a new genome based framework to illustrate how
cellular systems pass genetic information, and to understand why
the karyotype, and not the gene, defines genetic blueprint and is re-
sponsible for punctuated cancer evolution.
Methods: Using a somatic cellular model, we have traced the pattern
of karyotype evolution comparing gene and transcriptome profiling.
Specifically, key evolutionary transitions (e.g. immortalization, trans-
formation, metastasis, and drug resistance) were monitored by both
single cell and population profiles. Further synthesis was performed
to search for novel types of inheritance above gene/epigene and to
characterize fuzziness for chromosomal or karyotype coding. [1]
Conclusion: Data analysis and their synthesis with the genome
theory have led to the following conclusions: 1) chromosome or
karyotype codes for the address of genes within the nuclei. Such sys-
tem inheritance differs from gene-coded “parts inheritance”, defining
the network structure. Most cancers belong to different genome de-
fined systems; 2) genomic coding is less precise; rather, it is fuzzy.
Fuzzy inheritance defines a range of genetic information but not a
fixed status, which is the mechanism of inherited heterogeneity.
Since the degree of heterogeneity is inherited, a single cell can re-
store the cell population heterogeneity, and non clonal chromosome
aberrations (NCCAs) are common in cancer representing population
potential; 3) heterogeneity or “noise” defines cancer, and the outliers
are highly significant in cancer evolution. Heterogeneity can also be
generated from cellular adaptive processes, and thus represent an
unavoidable feature. Genome or karyotype heterogeneity can be rap-
idly achieved by genome chaos including massive fusion/dividing,
and possibly by the requirement of minimal survivable information
packages. Furthermore, the transitional population can be achieved
by the local cellular or tumor society where individual cells are not
sufficient enough to independently survive (but the emergence of
mixed cellular populations can); 4) the evolutionary mechanism of
cancer unifies the diverse molecular mechanisms. The multiple level
landscape model explains the limitations of focusing on cancer path-
way studies; and 5) the key cancer transition is mainly achieved by
new genome-mediated-macro-cellular emergence, while gene muta-
tions are mainly responsible for system modification. Survival and
adaptive landscapes differ in cancer, which suggests the importance
of separating macro and micro-cellular evolution [1-7].References
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Background
Metastasis accounts for nearly 90% of cancer-related mortality, but a gen-
etic mechanism remains elusive [1]. Previous research indicates that me-
tastasis risk increases with the DNA content of the primary cancer [2-11].
However, a coherent theory is still needed to explain metastasis [1, 12-13].
Carcinogenesis as a form of speciation
We and others have recently developed a theory that considers the
karyotypic origin of carcinogenesis, namely the speciation theory.
This theory contends that cancer is generated by random karyotypic
variations and evolutions of aneuploid cells from which a rare, au-
tonomous cancer cell emerges at aneuploidy-dependent rates [14].
The theory further predicts that cancers progress or evolve by auto-
matic karyotypic variations, because aneuploidy unbalances thousands
of genes—the more aneuploid the cancer the more likely it forms a
metastatic variant [14, 15].
Here we test the prediction of our theory that cancer-specific aneu-
ploidy catalyzes the karyotypic evolution of metastatic variants from
primary cancer.
Specifically, we asked:
1) Do primary cancers and corresponding metastases have related
yet individual karyotypes?
2) Does the degree of cancer-specific aneuploidy enhance the range
of cancer-specific karyotypic variation and by inference the risk of
metastasis?
Results
To answer these questions, twenty single metaphases from each primary
cancer were compared to determine how cancer-specific aneuploidy af-
fects karyotypic variability. We found that all cancers and corresponding
metastases had individual clonal, or quasi-clonal, karyotypes by methods
we have described recently [15]. Moreover, all metastases shared clonal
aneusomies with parental cancers, but also contained individual clonal
aneusomies.
Next, we asked how the degree of aneuploidy of different primary can-
cers affected the degree of aneuploidy of the corresponding metastases.
In these comparative studies, we found that the karyotypic heterogeneity
of near-diploid breast cancer HIM-2 was low, averaging only 1.1 non-
clonal aneusomies per 20 metaphases. Accordingly, the corresponding
metastasis HIM-5 also had a near-diploid karyotype with a similarly low
level of karyotypic heterogeneity.
By contrast, the karyotypic heterogeneity of hyper-triploid medulloblas-
toma M-458, the hyper-triploid liver cancer H2M, and the hypo-triploid
pancreatic cancer A13-B was high, averaging 17.6, 11.45, and 10.15 non-
clonal aneusomies per 20 metaphases, respectively. Likewise, their metas-
tases also had hypo-triploid and hyper-triploid karyotypes and similarly
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cancer-specific karyotypic heterogeneity, and thus inherent variability, is
dependent on cancer-specific aneuploidy.
In sum, our results showed that:
1) All metastases tested shared specific clonal aneusomies with the
corresponding primary cancers, but differed from parental cancers in in-
dividual aneusomies as well. This confirms the prediction of our theory
that metastases are sub-clones (or subspecies) from primary cancers.
2) The degree of aneuploidy of primary cancers was inversely propor-
tional to the karyotypic relationship between their metastases. This
confirms the prediction of our theory that the degree of aneuploidy
determines the degree of clonal heterogeneity, and thus the inherent
variability of cancers.
Conclusions
We conclude that cancers with a high degree of aneuploidy are highly
heterogeneous within cancer-specific margins due to high karyotypic
variability. Highly aneuploid cancers are thus at greater risk of metasta-
sizing than cancers with little aneuploidy. Therefore, the degree of
cancer-specific aneuploidy and, particularly, karyotypic variability are
key markers of metastasis risk.
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According to conventional wisdom, cancer is a disease process, aris-
ing from genetic errors in the command and control apparatus of a
precursor cell. Unregulated clonal expansion coupled with additional
genetic errors then follows, and, by Darwinian selection, the tumor
evolves to a more aggressive (and drug-resistant) phenotype. This is
the somatic mutation theory (‘M-Theory’). Accordingly, the solution
to the problem of clinical cancer requires the description of the mo-
lecular events mediating escape from growth constraints. This para-
digm depends on notions of causality and explanation, leading
inevitably to the concept of molecularly targeted therapy to achieve
both the required efficacy and the necessary selectivity; it also in-
volves the belief that such targets must exist, and are tractable.
Technical progress in genomic sequencing seemed to promise the
realization of this dream, but despite the torrent of big data, the clinical
utility has disappointed; few cancers possess truly ‘actionable muta-
tions’ and, except for chronic myeloid leukemia (an atypically simplified
cancer), the benefits of modern targeted drugs (while undeniable) are
transient, usually lasting about one year only. M-Theory has not deliv-
ered, and given the inherent and extensive obstacles, may never de-
liver [1]. Indeed, it now faces a Kuhnian crisis portending ‘model
revolution’. Unfortunately for causality-focused theorists, no deeper
level of drill-down exists beyond next-generation sequencing, and
hence no obvious alternative routes to a better causality-based model.
An alternative model re-focuses on the cancer cell as an organism
per se, a different form of life from the host. Malignant transform-
ation is seen as speciation, but a form of speciation that is radically
different from the usual allopatric speciation generally accounting for
the peripheral arborization of the tree of life. In this alternative view,
the cancer cell is not another type of metazoan closely related to our
phenotype, but in fact a protozoan, and not just an ordinary proto-
zoan; it is uniquely adapted to the very different geochemistry of the
ancient Proterozoic eon (circa 2.5BYA – 0.514MYA) via a stereotypical
set of peculiar characteristics common to all cancers.
The very commonality of these characteristics of the malignant
phenotype, in the face of so much genomic heterogeneity, is actually
a weakness of M-Theory which can only ascribe it to convergent evo-
lution; but this is not parsimonious, given the requirement that every
cancer throughout history and in every type of host is then obliged
to re-invent the same wheel each time. The more parsimonious ex-
planation is not M-Theory’s convergent evolution, but the unmasking
of a common inheritance dating back to the emergence of the
eukaryotic cell some 1.6BYA, in the hypoxic, acidotic and sulfurous
oceans of the mid-Proterozoic. This is atavism (‘A-Theory’), in which
the in-common traits of the cancer cell are either primitive (perhaps
including aneuploidy, ie species fluidity) or adaptations to the then
contemporaneous environment (e.g. Warburg Effect, proton pump)
of the original early eukaryote.
Therapeutic implications here depend not on causality-reversal, but
on the principle of recognition, in which cancer treatment results in
the release of destructive forces acting selectively on the cancer cell,
mediated by signature-attributes (including large-scale genomic al-
teration). Two illustrative ascendant examples are therapeutic DNA-
repair disruption (selectively pushing the cancer cell beyond viability)
and treatment with immune checkpoint inhibitors (selectively
unleashing the immune system on the neoantigen-painted cancer
cell, now seen as a foreign, ultimately because the deranged genome
manufactures an altered, hence antigenic proteome).
The concept of the target is thus expanded beyond the causal medi-
ators of the malignant phenotype, to include a variety of signature
differences which might have a common explanation in deep time.
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Important concepts
1. Manichean definition: Manichean comes from the word Mani, which
is the name of an apostle who lived in Mesopotamia in the 240’s, who
taught a universal religion based on what we now call dualism. If you
believe in the Manichean idea of dualism, you tend to look at things as
having two sides that are opposed. To Manicheans, life can be divided
neatly between good or evil, light or dark, love and hate, right and
wrong. So if your thinking is Manichean, you see things in black and
white. 2. “Nothing is black or white” Nelson Mandela. 3. “Don't reinvent
the wheel, just realign it” Anthony J. D’Angelo.
It is worth noting that a simple search in PubMed with the words ‘an-
euploidy cancer’ retrieves 17,740 publications and if we limit this
search to ‘Reviews’ one retrieves 2,257 publications as of 12/2016. In
other words we are not dealing with a new issue or revolutionary
concepts, nor we are dealing with a topic that is ‘white or black’ i.e.
somatic mutation vs. aneuploidy (or chromosomal instability). Every-
thing that could have been said about the relevance of aneuploidy and
somatic mutation in cancer initiation and progression has already been
proposed and written…long ago. There is no Holy Grail or ultimate
truth. The truth is never black or white is ‘gray’. Beating a death horse
on either side will take us nowhere and is truly irrelevant.
Progressive aneuploidy development is important in cancer initiation
and progression and so are mutations in cancer driver genes and so is
the Darwinian fitness of clones (not a new concept by ‘any’ means).
Experimental and observational evidence indicates that there is a clear
synergy between these phenomena. Who comes first? The answer (if a
single one exists) will have little if ‘any’ public health impact.
It is clear from decades old studies, by us and others, that somatic
mutations in cancer driver genes (e.g. Ha-Ras) are real, and are in-
duced by carcinogens (e.g. DMBA) at ‘sub-carcinogenic doses’ in
other words at doses in which no tumors develop during the lifespan
of the mouse. If the tissues (e.g. skin) bearing mutated clones are ex-
posed to ‘tumor promoter stimuli’ (e.g. TPA) that induces protracted in-
flammation and proliferation with consequential ‘random’ aneuploidy
development. Eventually non-random trisomies (trisomies of chr. 6 and
7) develop in premalignant lesions (papillomas). Importantly, there is a
selection for clones bearing trisomized chr. 7 carrying mutated Ha-Ras
allele with loss of Ha-Ras wt. alleles. In summary, no promotion = no an-
euploidy = no tumors, but also sub-carcinogenic DMBA= no tumors,
even in the presence of promotion [1-4].
My laboratory demonstrated very similar results in mammary cancer
models in which duplications trisomies and amplification affecting
the mutated Ha-Ras locus in rat chromosome 1 are observed upon
progression from hormone dependent tumors to hormone inde-
pendency. In this case the ‘promoter’ are the ovarian produced hor-
mones [5-6]. Other models will be briefly discussed [7-8].
Finally, in recent studies using Next Generation Sequencing ap-
proaches we determined that ‘pure’ Ductal Carcinoma in situ lesions
(premalignant by definition), already display mutations, transcrip-
tome and epigenetic changes indistinguishable from invasive
breast cancer. Importantly however >80% of pure DCIS lesion dis-
play evidence of aneuploidy and in some cases with absence of
cancer driver mutations, suggesting that aneuploidy may precede
mutation in some cases [9].
Humans are constantly exposed to a myriad of environmental ‘muta-
gens’ and we are also exposed to endogenous and exogenous ‘pro-
motional stimuli’ that induce proliferation and stimulate aneuploidy
development e.g. estrogens, progesterone, androgens, hormone re-
placement therapy, chronic inflammation etc. It is the synergy of
these insults, their consequences and how to minimize them what
matters, not what happens first.References
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Aims
To chart genetic intratumour diversity in childhood cancer over mul-
tiple anatomic locations and/or time points during treatment in order
to (1) delineate common routes of cancer cell evolution, (2) reveal
candidate mechanisms behind treatment resistance, and (3) gain in-
formation on intrapatient variability of clinical biomarkers.
Materials and methods
Patients were included based on the availability of two or more inform-
ative samples from the primary tumour, taken with a minimum intersam-
ple distance of 10 mm. A total of 50 patients with Wilms tumour (n = 20),
neuroblastoma (n = 20), or sarcoma (n = 10) have so far been subjected
to multiregional analysis of tumour tissue with high resolution whole
genome genotyping arrays (all patients) complemented in selected cases
by whole exome sequencing, targeted deep DNA sequencing, and RNA
sequencing. Between two and 20 tumour samples were analyzed per pa-
tient with a total of 229 informative tumour samples genotyped so far.
Results
The majority of cases exhibited intratumour genetic diversity with branch-
ing evolution, including variability of several suggested clinical biomarkers.
Subclones were the major arena of genome evolution in most primary tu-
mors. There were clear features of convergent evolution, including triso-
mies and monosomies of whole chromosomes as well as specific somatic
gene alterations such as TP53 mutation in Wilms tumors, CDKN2A/B dele-
tion in neuroblastoma, and CDK4 amplification in rhabdomyosarcoma. Gen-
etic patterns unique to anatomic sub-compartments in individual patients
had functional consequences for gene expression at the RNA and protein
levels. So far, four general trajectories of tumour evolution have been iden-
tified of which at least one strongly correlates to treatment resistance.
Molecular Cytogenetics 2017, 10(Suppl 2):21 Page 84 of 94Conclusion
Even in very young patients, high-risk cancer is a genetically dynamic
disease over space and time. Intratumour genetic diversity is common
and is a significant source of error in biomarker determination. Certain
evolutionary patterns may be useful as future clinical predictors.A8
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The iconic Tasmanian devil is the largest extant marsupial carnivore. It is
confined to the Australian island state of Tasmania, and is an important
part of the island’s ecology, as well as a significant tourist attraction.
Devils with gross facial tumours were first noticed in north east Tasmania
in 1995, and this condition spread over the subsequent decade. Devil
Facial Tumour Disease (DFTD) affects the mouth, nose and eyes, and
transcriptome analysis suggests a Schwann cell origin [1]. DFTD is invari-
ably and rapidly fatal even before significant metastasis [2]; it has now
killed 90% of devils and there is concern about extinction in the wild.
Chromosome analysis first showed that this tumour was transmissible.
The devil has a very conserved (almost ancestral marsupial) karyotype
of 2n = 14 shared by many species in the Family Dasyuridae. Karyo-
types of tumour cells were very abnormal – but notably they were all
the same, suggesting that a devil tumour cell itself is the pathogen [3],
and is transmitted between adult animals by biting during feeding and
mating. This clonal theory was supported by the finding that tumour
cells from different animals had the same microsatellite profile and
MHC type, which was different from those of host animals.
Chromosome painting revealed that two chromosomes of the tumour
karyotype were multiply rearranged, suggesting a chromothrypsis event
[4]. The X and chromosome 1 (misidentified as 2 in the first and subse-
quent DFTD papers) were fragmented and bits inserted at several loca-
tions. The absence of Y chromosome sequences, and heterozygosity of
some X-borne genes implies that the founder animal was a female. The
tumour karyotype is remarkably stable. However, over the last few years,
several minor structural variants have been identified, as well as a tetra-
ploid strain [5], and there is some suggestion of differences in transmis-
sability. However, no sign of attenuation has been reported.
Remarkably for such a rare condition, an unrelated transmissible fa-
cial tumour (DFTD2) has recently been detected in animals in south-
ern Tasmania [5]. This may relate to the paucity of MHC variation in
the devil population and ferocious devil social interactions, or could
reflect an unusual imprinted telomere regulation in devils and their
dasyurid relatives [6]. A difference between long telomeres on the
paternal chromosome set and short on the maternal set is main-
tained throughout life, but is obliterated in the tumour cells.
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Background
Genomic instability produces genetic and phenotypic heterogeneity
that allows a cancer cell population to adapt to and survive harsh mi-
croenvironments. Cytotoxic stresses including drug treatment-
mediated stress and transgenic manipulations may intensify genomic
chaos of tumor cells and favor the emergence of new phenotype
variants, increasing the evolutionary potential of a tumor [1,2]. To
provide evidence of karyotype-phenotype evolution as an adaptive
response to stressful conditions, we characterized chromosomal in-
stability (CIN, clonal and non-clonal chromosomal aberrations, CCAs/
NCCAs) and phenotypic changes of cancer cell lines after applying
the different cytotoxic stresses.
Materials and methods
A panel of the long-term temozolomide, temsirolimus, and U0126-
treated U251, T98G, and C6 glioblastoma cell lines was established.
HEK293_pcDNA3.1, HEK293_CHI3L1 and HeLa_CHI3L1 cell lines were
derived by stable transfection with pcDNA3.1 empty plasmid or tumor-
associated CHI3L1 cDNA in pcDNA3.1 vector. Genomic and phenotypic
changes were analyzed by conventional cytogenetics, array CGH, cell
viability assay, trypan blue exclusion assay, soft agar colony formation
assay, scratch wound healing assay, transwell invasion assay, quantita-
tive polymerase chain reaction, and Western blotting.
Results
A stable transfection of either pcDNA3.1 or pcDNA3.1_CHI3L1 into
HEK293 cells or HeLa cells promoted genomic changes. HEK293_-
CHI3L1 and HeLa_CHI3L1 cells demonstrated the opposite growth
characteristics [3]. The long-term treatment with DNA-damaging drug
temozolomide increased genomic diversity of U251 and T98G cells
but selected genetically stable C6 clones [4]. The long-term treat-
ment with mTOR inhibitor temsirolimus or MEK1/2 inhibitor U0126
increased genomic heterogeneity of U251 and T98G cells [5]. The
long-term drug-treated cells demonstrated distinct, cell line- and
treatment-dependent, phenotypic changes. An increase of resistance
to drug re-challenge was the only predictable phenotypic trait intrin-
sic to all long-term drug-treated tumor cells [4,5].
Conclusions
A stable transfection of plasmid DNA into tumor cells can result in
chromosomal abnormalities and phenotypic changes challenging
an assumption that empty vector-transfected cells preserve the
cytogenetic and phenotypic characteristics and represent the ad-
equate control in transfection experiments [6]. The opposite growth
characteristics of CHI3L1-transfected tumor cells suggest that the ef-
fects and functions of a (trans)gene can be opposite and versatile
in cells with the different genetic networks, defined by the genome
context [7]. The long-term drug treatment selects resistant
genotype-phenotype variants or generates novel versatile pheno-
types by increasing genomic chaos. Genomic instability-driven
multilayered heterogeneity and complex reprogramming of signal
transduction pathways are responsible for adaptation of a tumor
cell population to cytotoxic stresses of different nature.
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Two out of three tumors display an abnormal chromosome content,
a state defined as aneuploid. Aneuploidy is the result of cells misse-
gregating chromosomes during mitosis, also known as chromosomal
instability (CIN). Despite being a hallmark feature of cancer cells, an-
euploidy inhibits cell proliferation of non-transformed cells, suggest-
ing that cancer cells have acquired mutations that help them cope
with the disadvantages of aneuploidy. This makes aneuploidy a
promising target for cancer therapy [1]. To better understand how
cells cope with aneuploidy in vivo, we developed conditional knock-
out mouse models, in which we can provoke a high rate of constant
chromosome missegregation events in tissues of choice. Our models
have allowed us to induce highly aneuploid cancers in various tissues
in a p53-deficient setting, including liver and T-cells in a highly repro-
ducible fashion. Surprisingly, when we measured the average DNA
content in a large number of these aneuploid tumors, we found that
tumors exhibited recurrent copy number changes in each tumor for
some chromosomes, but not others [2]. This suggested that either
the tumors had overcome the mutations that provoked the constant
chromosome missegregation or that the recurring copy numberchanges were outcompeting the missegregation rate. To test this, we
performed single cell sequencing of primary tumor cells and devel-
oped AneuFinder, a dedicated software tool to quantify intratumour
karyotype heterogeneity [3]. AneuFinder analysis of our murine aneu-
ploid lymphoma revealed dramatic intratumour heterogeneity, while
confirming selection for the recurrently gained/lost chromosomes, in-
dicating ongoing chromosome missegregation can yield seemingly
stable aneuploid tumors that display high-grade intratumour hetero-
geneity. We are currently analyzing human tumors and our preliminary
findings are indicating that intratumour heterogeneity rates can be very
different between aneuploid tumors. As ongoing CIN and the resulting
heterogeneity might predispose tumors to become therapy resistant
[4], unbiased single cell karyotype assessment might become an essen-
tial tool in the future to stratify cancer therapy.
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Copy number variations (CNVs) comprise microscopically visible harm-
less CNVs (CG-CNVs), known as heteromorphisms, as well as submicro-
scopic CNVs in the size of kilo- to megabasepairs (MG-CNVs). While CG-
CNVs are known since decades, MG-CNVs were discovered as major
part of human genome in 2004. CG-CNVs as well as MG-CNVs can be
found in clinically healthy individuals as well as cancer patients [1]. Here
I provide a review not given/published before, on what is known today
on the still too little studied harmless human CG-CNVs and MG-CNVs
and their implications for cancer research and diagnostics.
Due to technical issues, only in CG-CNVs heterochromatic and
euchromatic variants can be distinguished, while in MG-CNVs exclu-
sively euchromatic variants can be detected. Heterochromatic CG-
CNVs already lead in leukemia cases to false positive ‘detection’ of
monosomies (like -7), due to a “cen-“ heteromorphis in one hom-
ologous chromosome. Also inversion heteromorphisms of chromo-
some 9, or less known euchromatic variants of 8pter or 16p11.2,
can be confused with associated malignancy and meaningful ac-
quired aberrations. Maybe due to the sheer amount of them it is
yet completely unclear and not studied, if MG-CNVs may be associ-
ated with tumor subtypes, or not.
In summary, CG-CNVs and MG-CNVs are considered not at all, or at
least not enough, yet during evaluation and reporting; this is true for
constitutional as well as cancer genetics. Remembering the so-called
two-hit model, suggesting that combination of per se harmless CNVs
may lead to clinical aberrations if they are present together in one
patient, makes the difficulties we are facing clearly evident, when
thinking about which genetic changes are relevant for a disease and
which are not.
References
1. Liehr T. Benign & Pathological Chromosomal Imbalances. Microscopic
and Submicroscopic Copy Number Variations (CNVs) in Genetics and
Counseling. 1st edition. New York. Academic Press; 2014.
Fig. 1 (abstract A12). Diagrammatic representation of the
experimental protocol used to generate tetraploid cell populations and
list (right) of the analyses subsequently performed on such populations.
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Background
Many lines of evidence have led to a widely accepted model for
how tetraploidy may act as a precursor of chromosomal instability
in cancer [1]. The model proposes that tetraploid cells, because of
supernumerary centrosomes, will undergo highly defective chromo-
some segregation in mitosis. Such defective mitoses would gener-
ate cells with abnormal karyotypes and abnormal centrosome
numbers, both of which are common in cancer cells. However, we
[2] and others [3] have found that tetraploid cell clones with nor-
mal centrosome numbers can evolve after cytokinesis failure. The
goal of our study was to identify the events that lead to the emer-
gence of such clones, with the idea that this will help us under-
stand how tetraploidy may be linked to the aneuploidy and extra
centrosomes seen in cancer cells.
Materials and Methods
To achieve our goal, we examined the short-term evolution of
experimentally-generated tetraploid cell populations. Such popula-
tions were generated by experimentally inhibiting cytokinesis in
DLD1 cells (2 N) to obtain a population of prevalently tetraploid
(4 N) cells, which also carried extra centrosomes (Fig. 1).
Results
We found that first generation tetraploid cells frequently, but not al-
ways, divide in a multipolar fashion. Moreover, chromosomes from
multiple poles often cluster into a single daughter cell during cell
division, but cell death and cell cycle arrest occur at high rates imme-
diately after tetraploidization. By performing chromosome counts in
the evolving population at regular time intervals, we found that
highly aneuploidy karyotypes (between 2 N and 4 N) are generated
as a result of multipolar divisions in tetraploid cells. However, such
highly aneuploid karyotypes are quickly eliminated from the prolifer-
ating population and at day 12, two subpopulations remain with
modal chromosome numbers of 46 and 90-92. Preliminary modeling
efforts suggest that multipolar divisions would frequently produce
cells with nullisomy, which may explain the reduced viability of cells
produced by multipolar divisions. We also found that the fraction of
cells possessing >2 centrosomes quickly decreases to very low levels
during the 12-day period, despite a large fraction of the cell popula-
tion still displaying near-tetraploid karyotypes at day 12. Finally, we
determined that the evolved population displays high chromosome
number heterogeneity and can form larger colonies in soft agar com-
pared to the parental (2 N) cell population.
Conclusions
Overall, our data indicate that extra centrosomes are quickly lost
during initial evolution of tetraploid cell populations. However, the
remaining population displays high karyotypic heterogeneity, indi-
cating that this, rather than the abnormal centrosome number may
explain the tumorigenic potential of tetraploidy.
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Aneuploidy, an unbalanced number of chromosomes, severely affects
cell physiology and is widespread in pathologies such as cancer. In
model systems, whole-chromosome aneuploidy results in impaired pro-
liferation, replication stress, disturbed proteostasis, and specific changes
to the transcriptome and proteome [1-10]. Yet, the molecular mecha-
nisms underlying these characteristic changes are not well understood.
To elucidate common molecular mechanisms, we analyzed the con-
sequences of aneuploidy in human cells from a systems biology per-
spective. To this end, we acquired genome, transcriptome, proteome
and microRNAome data from a series of previously established hu-
man model aneuploid cell lines with one or two extra chromosomes
[11]. Our large-scale comparison of the aneuploid transcriptomes re-
vealed that the gene expression changes affect common cellular
pathways independently of the cell line, type, and origin of aneu-
ploidy [12]. We found that the conserved pathway deregulations are
largely similar to the transcriptome changes after autophagy inhib-
ition or in heat shock transcription factor- (HSF1) deficient cells.
Moreover, the aneuploid proteome closely resembles the proteome
after HSP90 inhibition [4]. This is in good agreement with our find-
ings that aneuploid cells suffer from proteotoxic stress characterized
by impaired HSF1 activation, HSP90 protein folding deficiency, and
downregulation of HSP90 client proteins.
We hypothesized that microRNAs may play an additional role in the
complex response to aneuploidy. Small RNA sequencing data ana-
lysis revealed that the microRNAome is strongly altered in aneuploid
cells. Moreover, integrated analysis of microRNAome, transcriptome
and proteome data suggests that the deregulated microRNAs nega-
tively affect the development, growth and proliferation of aneuploid
cells. Additionally, we identified the microRNA hsa-miR-10a-5p to be
commonly upregulated in the analyzed cell lines. Subsequent experi-
ments suggested that hsa-miR-10a-5p protects aneuploid cells from
starvation-induced shutdown of translation of ribosomal proteins.
Taken together, this systems biology perspective demonstrates that
the common phenotypic response to aneuploidy is reflected in con-
served changes to the microRNAome, transcriptome, and proteome.
Moreover, our results indicate that disturbed proteostasis significantly
shapes the response to aneuploidy and its effects are manifested in
both transcriptome and proteome. In addition, we show that the
deregulated microRNAome contributes to the response to aneu-
ploidy by negatively affecting the growth of aneuploid cells on one
hand and positively regulating the resistance to stress on the other
hand. Our “omics” approach not only facilitates an understanding of
the common consequences of aneuploidy by comparison of many
different aneuploid cell lines, but also points to new avenues of re-
search into aneuploidy in cancer.
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Background
Aneuploidy, defined as structural and numerical aberrations of the
chromosomes, continues to draw attention as an informative effect
biomarker for carcinogens and reproductive toxicants [1]. Aneuploidy
is a hallmark of cancer and precancerous lesions, some of the most
powerful carcinogens are capable of inducing aneuploidy in different
tissues [2-6]. The higher the degree of aneuploidy in precancerous
lesions, the higher the risk of malignant progression [7-16].
On the other hand, sperm aneuploidy represents both a biomarker of
reproductive toxicity, associated with infertility, pregnancy loss and a
number of congenital abnormalities [17], and also a biomarker of neo-
plastic and preneoplastic lesion for testicular cancer [18, 19]. In fact
aneuploid cells from germinal neoplasias are present in the sperm of
patients with testicular cancer. At least 7 substances are currently
known to increase sperm aneuploidy [20]: phthalates [21], styrene [22],
organophosphates [23], carbaryl [24], fenvalerate [25], lead [26, 27], and
benzene [28]. Six of these 7 substances are also known or suspected
carcinogens [29]. Exposures to DDT and PCBs, substances already classi-
fied as carcinogens, have been also recently associated with increased
rates of sperm aneuploidy in human [17]. We are currently investigating
sperm aneuploidy in association with the exposure to different pesti-
cides, including glyphosate and pyrethroids, and chemicals, in particu-
lar per- and polyfluoroalkyl substances (PFAS), studying both humans
cohorts and experimental animal models.
Materials and Methods
The animal model will be Sprague Dawley rats from the colony of the
Cesare Maltoni Cancer Research Center, Ramazzini Institute. This model
has been used for over 40 years for toxicology and carcinogenicitybioassays. Sperm obtained from Sprague Dawley rats will be analyzed
through mFISH laser-scanning microscopy by the George Washington
University, following similar procedures already in use for humans [17].
Results
As we recently pointed out [1], the association between sperm aneu-
ploidy and chemical exposures has been scarcely tested in toxico-
logical and epidemiological studies. Our recent results highlight the
value of this biomarker through observational studies in humans ex-
posed to pesticides and other chemicals [17]. Our preliminary results
seem to indicate that mFISH, in combination with laser scanning mi-
croscopy, is a suitable technique for sperm aneuploidy analysis in
Sprague Dawley rats exposed to chemicals.
Conclusions
Aneuploidy is a biomarker that may indicate exposures to substance
that act as carcinogens and reproductive toxicants [1]. With the
advent of automated chromosome counters and Laser Scanning
Microscopy [30], sperm aneuploidy assessment has become much
faster and reliable, in both human and experimental models. There-
fore new toxicological and epidemiological studies, using state-of
the art mFISH techniques, are necessary to evaluate the burden of
chemicals that are capable of inducing sperm aneuploidy. Specific
attention should be given to pesticides because of their widespread
use and their frequent association with sperm aneuploidy, repro-
ductive toxicity and carcinogenicity.
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We have described transcriptome instability (TIN) as a novel phenotype
of colorectal cancer [1]. These findings were followed up by investiga-
tion of genome-scale and exon-level mRNA abundance levels from
altogether 555 patients with primary cancers from seven different ana-
tomical sites. We developed algorithms to score the sample-wise and
transcriptome-wide amounts of alternative splicing. We found that TIN
is a pan-cancer characteristic of carcinomas [2]. Interestingly, the
amounts of aberrant exon skipping and inclusion in tumors, correlate
significantly with expression levels of splicing factor genes. This was
the case in cancers of the breast, cervix, colorectum, lung and prostate.
Thus, we see a plausible biological explanation for the observed
splicing variation.
Further, through whole-transcriptome sequencing, we and others
see that there are large amounts of chimeric RNA molecules which
are expressed both in malignant and non-malignant tissues [3-5].
These are commonly produced by mis-splicing (after RNA polymer-
ase read through of adjacent genes or through trans-splicing of dis-
tantly located genes). Many of the chimeric RNAs are ectopically
expressed in cancer samples, although not yet linked to the TIN
phenotype. For example, the fusion transcript SLC45A3-ELK4 is ubi-
quitously expressed in both normal and malignant tissues from
prostate, but to a much higher degree in a subset of cancer sam-
ples [6-7; and unpublished]. To speed-up discovery of fusion tran-
scripts, we developed a protocol for highly multiplexed rapid
amplification of cDNA ends (RACE) coupled by high-throughput se-
quencing of pooled RACE-products from many patients (RACE-seq).
We have used this RACE-seq approach to identify novel fusion tran-
scripts from colorectal cancers [8].
Conclusion
We see an enormous variation in the RNA-transcript processing
across cancer samples. This is commonly due to misregulation of the
pre-mRNA splicing machinery, which also may generate chimeric
RNA molecules.
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Cytogenetic aberrations have been associated with diagnosis and
prognosis of common human leukemias with increasing frequency.
The detection of the Philadelphia chromosome with the t(9;22) trans-
location in chronic myeloid leukemia (CML) was the first chromosome
aberration regularly associated with a definite type of leukemia. As mo-
lecular correlate of the t(9;22)translocation the juxtaposition of the ABL
oncogene of chromosome 9 and BCR sequences of chromosome 22
was identified which results in a BCR-ABL fusion transcript. Genetic in-
stability induced by BCR-ABL is thought to cause additional chromo-
somal aberrations (ACA) that promote clonal evolution, drug resistance
and disease progression [1] pointing to a cooperation between the
ABL-oncogene and aneuploidy.
Cytogenetic aberrations have been identified as diagnostic and prog-
nostic markers also in chronic lymphocytic leukemia (CLL), acute mye-
loid leukemia (AML) and acute lymphoblastic leukemia (ALL): A new
prognostic score has been proposed for CLL that uses cytogenetic ab-
errations to guide personalized therapy [2]. The 2016 revision of the
World Health Organization classification of myeloid neoplasm and
acute leukemias includes cytogenetic and molecular data for diagnostic
and prognostic classification [3]. The new recommendations of the
European LeukemiaNet for the management of AML [4] are based
on cytogenetics and mutations for stratification of AML according
to prognosis and targets for therapy.
Not all additional cytogenetic aberrations are prognostically equally
relevant. In CML, only “classic “ major route aberrations [+8, +Ph,
i(17)(q10),+19] at diagnosis have been associated with a poor prognosis
[5], whereas minor route aberrations (balanced or unbalanced) have no
negative impact [6]. In an analysis of ACA appearing during the course
of CML more types of ACA (particularly -7 and 3q26) were identified
that were associated with inferior survival [7]. ACA newly arising under
therapy were defined as indicating clonal evolution and a poor progno-
sis by ELN management recommendations for CML [8].In a correlation of ACA with blast counts it was determined that
ACA, in particular major route ACA, but also abnormalities of chro-
mosomes 3,7,21 and 17 precede blast increase. The impact of
minor route ACA could be eliminated by imatinib indicating that
minor route ACA may not be relevant for blastic progression and
may rather be bystanders than drivers [9].
In summary, chromosomal aberrations may determine prognosis and
survival in virtually all types of leukemia.
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Background
“Active surveillance” (AS) of low-grade, localized cancers of the
prostate represents a conservative strategy that renounces ag-
gressive therapy with unpleasant side effects. It is suitable for
about 30% of newly diagnosed cases and depends on a low
Gleason-score (GS) of 6 or 7a. As this subjective score is bur-
dened by a low interobserver reproducibility of about 60%,
>30% of AS-patients have to face a progress of their cancer
within four years, that makes active therapy necessary. The de-
gree of malignancy of most cancers depends on the degree of
chromosomal aneuploidy. This can indirectly be quantified by
automated measurements the DNA-content of thousands of
cancer cells, called “DNA-Karyometry.”
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In a prospective level 1b-study on 80 untreated prostate cancer pa-
tients under AS we have compared the ability of the subjective
Gleason-Score (locals and reference pathologist R.E.) and the DNA-
Grade of Malignancy (DNA-MG) to predict a biochemical or clinical
progress within 4,1 years. Cancer cells were obtained from residual
biopsies by enzymatic cell separation. After Feulgen staining at least
300 up to 30.000 cancer-nuclei have automatically been measured
by TV-image-analysis, applying digital nuclear classifiers using a com-
puterized microscope (MotiCyte-auto, Motic, Xiamen, P.R. China).
DNA-MGs 1-4 have been distinguished according to the proposal of
the ESACP (2001). GS >6 and DNA-MG >1 had been taken as predic-
tors of progression. Proven stages pT > =3 and PSA-doubling times <
36 months were taken as indicators of progression. Other definitions
have also been analyzed.
Results
While interobserver reproducibility of GS was found to be 55%, that
of DNA-grading amounted to 92,7%. Sensitivity, specificity, positive
and negative predicive values for reference pathologists GSs were:
22,2%, 93,1% 33,3% and 79,4%, that for DNA-grading: 100%, 80,0%,
33,3% and 100%.
Conclusion
By applying automated DNA-karyometry on residual prostate cancer
biopsies additional to the GS, progressions of prostate cancers can
be predicted or excluded more accurately. Thus patients can rely
more safely on the AS-strategy that avoids side effects and complica-
tions of most active therapies.
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Changes in nuclear structure have long been used as a major diag-
nostic tool to detect cancer [1]. Although it is known that nuclear
architecture is altered in cancer, less is known about the concomitant
changes in CT organization. There is growing evidence that chromo-
some territories (CT) have a probabilistic non-random arrangement
within the cell nucleus of mammalian cells including radial position-
ing and preferred patterns of interchromosomal interactions that are
cell-type specific [2-7]. While it is generally considered that the three-
dimensional (3D) arrangement of genes within the CT has a connec-
tion to genomic regulation, the spatial arrangement of some genes
are more influenced by expression than others [8]. We examined the
interchromosomal spatial positioning of a subset of human chromo-
somes in the human breast cell line MCF10A (10A) and its malignant
counterpart MCF10CA1a (CA1a) [9]. Each CT was in close proximitywith a similar number of other CT except the inactive CTXi and the
gene rich CT17. The inactive X had lower levels of interchromosomal
partners in 10A which increased strikingly in CA1a. In contrast chr17
had higher levels of interchromosomal interactions. Major alterations
from 10A to CA1a were detected in the pairwise interaction profiles
which were subdivided into five types of altered interaction profiles.
Interestingly, we identified a pattern of differential interchromosomal
interactions for each homolog of a given chromosome. We also
found differential patterns with regard to nucleoli [10]. Global data
mining program termed the chromatic median calculated the most
probable overall association network for the entire subset of CT. This
interchromosomal network was drastically altered in CA1a. Future
studies will include the impact of aneuploidy on higher order chro-
matin organization. While we have identified global increased levels
of transcription on aneuploid chromosomes, this relationship is not
absolute. We conclude that CT undergo multiple and preferred inter-
actions with other CT in the cell nucleus and form preferred-albeit
probable-interchromosomal networks. This network of interactions is
highly altered in malignant human breast cells. Aberrations in the
karyotype of cancer cells is also expected to alter these interchromo-
somal interactions. It is intriguing to consider the relationship of
these alterations to the corresponding changes in the gene expres-
sion program of malignant cancer cells.
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Approximately 10-15% of acute myeloid leukemia (AML) cases are
categorized as “complex karyotype”, defined as having three or more
chromosome aberrations in the absence of prognostically-favorable
rearrangements (t(8;21), inv(16), and t(15;17)) [1]. Complex karyotype
AML is associated with unfavorable prognosis, and molecularly-
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harbor multiple chromosome abnormalities, in many instances 10 or
more, including numerical gains and losses, as well as varied struc-
tural rearrangements. Chromosome gains and losses are thought to
impact the expression levels of residing oncogenes and tumor sup-
pressors [2, 3]. However, the contribution of chromosome structural
rearrangements has been less clear.
To investigate the impact of chromosome aberrations in complex
karyotype AML, we carried out whole-transcriptome RNA sequencing
(RNAseq) of 65 cases. All cases were associated with detailed clinico-
pathological annotations, cytogenetics, and SNP/CGH array profiles.
RNAseq reads were aligned to the genome, and candidate gene fusions
identified as reads spanning two different genes, using ChimeriScan
and TopHat-Fusion. Selected fusions were independently verified by
Nanopore sequencing.
In all, RNAseq analysis uncovered 55 high-evidence gene fusions in
30 (46% of) complex-karyotype AML samples. Nearly all fusions were
previously unreported in AML. No gene fusions were recurrent,
though some genes recurred as 5’ or 3’ partners. About one-quarter of
fusions contained a known AML gene (e.g. RUNX1, KMT2A) fused to a
gene previously unreported in AML. The majority of fusions comprised
partners where neither was previously associated with AML, though
many had plausible leukemic roles or targetable domains (e.g. cell
surface receptors, kinases, other enzymes). Mechanistic studies of
novel gene fusions are ongoing to elucidate functional roles.
The chromosome aberrations that comprise complex karyotype AML
appear not only to impact gene expression levels, but also to conceal
cryptic gene fusions that may contribute to leukemogenesis.
References
1. Mrozek, K, Cytogenetic, molecular genetic, and clinical characteristics of acute
myeloid leukemia with a complex karyotype. Semin Oncol 2008;35(4):65-77.
2. Pollack, JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R,
Botstein D, Borresen-Dale AL, Brown PO. Microarray analysis reveals a major
direct role of DNA copy number alteration in the transcriptional program of
human breast tumors. Proc Natl Acad Sci USA 2002;99(20):12963-8.
3. Salari K, Tibshirani R, Pollack JR. DR-Integrator: a new analytic tool for
integrating DNA copy number and gene expression data. Bioinformatics
2010;26(3):414-6.
A20
Chromosomal instability and cancer cell stemness under induced
replication stress and extreme telomere dysfunction
Fani-Marlen Roumelioti, Maria Chiourea, Christina Raftopoulou,
Sarantis Gagos
Center for Experimental Medicine and Translational Research, Biomedical
Research Foundation of the Academy of Athens Greece (BRFAA),
Soranou Efesiou 4, Athens 115 27, Greece
Correspondence: Sarantis Gagos (sgagos@bioacademy.gr)
Molecular Cytogenetics 2017, 10(Suppl 2):A20
Chromosomal instability (CIN) in neoplasia generates extensive intra-
tumor genomic heterogeneity that shapes the multistep process of
malignancy and burdens onco-therapeutics. Human tumors and im-
mortalized cell lines utilizing the Alternative lengthening of telo-
meres exert high rates of ongoing telomere dysfunction [1-3]. In ALT
cells, numerical chromosomal aberrations are very frequent, while
structural rearrangements affect almost every single chromosome [1-3].
This challenging context provides excellent grounds to study CIN in a
single cell basis. Many cancers are considered to be driven by cancer
stem cells (CSCs) that may differentiate into a variety of cell types while
maintaining the ability to self-renew. To identify putative CSCs in the
ALT-pathway, we combined single cell analysis by M-FISH/SKY, with a-
CGH and Immunocytochemistry, in a panel of human ALT cell lines, be-
fore and after exposure to ionizing radiation, topoisomerase inhibition,
or DNA replication-stress. Exogenous genotoxic stress triggered in-
creased rates of random structural and numerical chromosome aberra-
tions, polyploidization, as well as elevated frequencies of cancer cells
expressing the mesenchymal CSC marker CD133. Enrichment of CD133
+ cells in culture, showed significant decrease at the frequencies of
telomere dysfunction foci and in random structural CIN, whereas therates of whole genome endoreduplication, or polyploidy reduction,
were highly elevated. Upon induced DNA damage, molecular karyotyp-
ing revealed several novel clonal structural chromosomal rearrange-
ments distinguishing the challenged from the control cells. However by
aCGH, the insulted ALT genomes displayed a remarkable propensity to
maintain the major genomic imbalances of the control cells suggesting
a trend that preserves monoclonality. Interestingly, CIN was unequally
distributed between co-dividing cells both in control and challenged
cell cultures. The minority of mitotic cells that appeared resistant to
structural CIN, were found to represent products of polyploidization
reduction, and corresponded well to the percentages of CD133+
cells. Our results demonstrate a continuous process of ALT cancer
genome homeostasis that relies on polyploidization and polyploidy
reduction and may be related to genotoxic therapy resistance and
cancer cell stemness.
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First genetic cancer theory: Specific aneusomies cause cancer
By 1914 cancers were known to carry abnormal numbers of chromo-
somes and Theodor Boveri had discovered that individual chromo-
somes carry specific subsets of the cellular genome. On this basis
Boveri advanced the theory that losses of specific chromosomes
with growth “inhibitory” functions and gains of specific chromo-
somes with growth “stimulatory” functions are the causes of cancer
[1]. This theory set off a search for the predicted, abnormal ‘cancer-
specific’ chromosomes.
But, contrary to Boveri’s theory, the chromosomal abnormalities of
all cancers tested were individual: No two cancers shared the same
aneusomies [2-5]. According to the most recent account of the Na-
tional Cancer Institute’s NCI-Mitelman database all 66,872 cancers
recorded by November 2016 had individual sets of chromosomes
or karyotypes [6].
No theory to explain the individuality of the karyotypes of
all cancers
Despite the abundance of evidence for individual karyotypes in in-
dividual cancers, there is no theory to explain the individuality of
cancer karyotypes in current textbooks [3, 7]. In view of this endless
variety of cancer karyotypes most cancer researchers abandoned
Boveri’s theory in favor of the theory of causal mutations, and thus
regarded the individual karyotypes of cancers as “epiphenomena”
[3, 8-10] or “Folgeerscheinungen” [11] or “consequences” [7] of the
“instability” of cancer karyotypes [12, 13]. This confirms Gunther
Stent’s famous theory for experimental scientists: “The best results
are useless, if they cannot be confirmed by theory!”
In view of this, Is it possible that cancer researchers have overlooked
an established model for the generation of new functions and pheno-
types by altering the karyotypes?
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There is, indeed, a classic biological mechanism of altering pheno-
types via karyotypes in countless variations – namely speciation.
By realizing that autonomy, individual karyotypes, transcriptomes
and phenotypes and low probability of occurrence compared to mu-
tation [12, 14-18] are all shared by carcinogenesis and speciation – a
small group of cancer researchers has recently studied carcinogen-
esis as a form of speciation. Their names and abstracts are listed in
the proceedings of this conference and representatives of each
group have spoken at this conference, namely Mark Vincent, Henry
Heng, Aleksei Stepanenko and us.
Mechanism of carcinogenesis by speciation. According to the speci-
ation theory carcinogens or spontaneous accidents initiate carcino-
genesis by inducing random aneuploidy. Aneuploidy then catalyzes
random karyotypic variations automatically by unbalancing thou-
sands of genes. Because of the very low probability that random
karyotypic variation would form the karyotype of a new autonomous
species, the karyotypes of cancers would be individual and clonal –
much like those of conventional species. This would predict the
karyotypic individuality [6] and clonal origins of cancers [18, 19].
Clonal karyotypes, the most critical prediction of speciation theory. To
test this critical prediction of the speciation theory - we have devel-
oped a technique in which we detect chromosomal clonality even
if a fraction of the chromosomes of a karyotype is non-clonal – as is
typical for cancers [20-22]. Accordingly, we compared the copy
numbers of individual chromosomes of 20 cancer karyotypes in 3-
dimensional tables, hence termed karyotype arrays. The numbers of
individual chromosomes are on the x-axis, the copy numbers of the
chromosomes on the y-axis, and the numbers of karyotypes ana-
lyzed on the z-axis [22, 23]. The resulting parallel (clonal) lines
formed by the karyotype arrays of all cancers tested so far, includ-
ing breast, colon, cervical, pancreatic, and liver cancers directly con-
firmed the speciation theory [18, 21-26].
In the meantime complete genome sequencing of cancer cells un-
dermines the conventional mutation theory [7, 12, 14, 27-30] by an
inflation of thousands of new cancer-specific, but untested muta-
tions [31-33] – leaving the speciation theory as the only probable
alternative.
Conclusion
We conclude that cancers are generated and maintained by individual
clonal karyotypes and corresponding transcriptomes as a whole –
much like conventional species. Thus cancers are species of their own.
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degree of aneuploidy correlates with tumor aggressiveness and poor
prognosis. Therefore, studying the cellular processes affected by aneu-
ploidy can improve our understanding of its role in tumor biology.
Our previous studies in aneuploid yeast strains revealed that slow
proliferation, increased genomic instability and altered metabolism
are characteristics shared by aneuploid cells independent of their
chromosomal abnormalities. Subsequent studies showed that the
aneuploidy-associated phenotypes first discovered in yeast are
also present in mouse and human aneuploid cells. This suggests
that the cellular responses to aneuploidy are conserved from yeast
to humans.
Identifying the cellular processes affected by aneuploidy can reveal
how specific genomic alterations help aneuploid cancer cells survive,
adapt and thrive despite harboring an abnormal genome.
Due to the negative effects of aneuploidy on cellular physiology
and increased genomic instability, selective pressure drives the ac-
quisition of genomic alterations that improve cellular fitness of an-
euploid cells. Here, we identified several mutations in genes that
regulate sphingolipid synthesis to affect the fitness of aneuploid
cells, suggesting that these lipid molecules play an important role
in the physiological responses to aneuploidy.
Sphingolipids are synthesized from serine and palmitoyl-CoA. Both
long-chain bases (LCBs) and ceramides are sphingolipid intermedi-
ates that function as signaling molecules and are rapidly induced
upon stress. While ceramides mainly serve to slow cell cycle pro-
gression, LCBs activate transcriptional responses and signaling
pathways associated with cell wall integrity and survival. Here, we
used genetic and biochemical approaches to identify specific
sphingolipid molecules that modulate the fitness of aneuploid cells.
Transcriptome and proteome analyses of the disomes harboring a
mutation that increases LCBs and improves fitness indicate that
these molecules regulate membrane protein composition, RNA bio-
synthesis, and several metabolic pathways that rely on mitochon-
drial function. Our results provide a better understanding of the
physiological role of sphingolipids in controlling the fitness of an-
euploid cells. Determining the mechanisms that control the fitness
of aneuploid cells can be exploited to target aneuploid cancer cells
and to ameliorate the deleterious effects of aneuploidy in Down
syndrome or neurodegenerative diseases.
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Most human carcinomas contain genomically unstable cells and ex-
press telomerase activity. Widespread instability is first observed
in vivo at the pre-malignant stage (such as DCIS in breast cancer),
and in vitro as finite cells with critically shortened telomeres
approach replicative senescence. We have proposed that this
telomere-dysfunction induced instability is needed to generate the
errors required for telomerase reactivation (immortalization), while
also generating many additional “passenger” errors that can be car-
ried forward into the resulting carcinomas. Genomic errors that
occur prior to immortalization may influence the cancer phenotype
and form the basis for ongoing genomic instability in the malignant
cells through breakage-fusion-bridge cycles.
We have postulated that immortalization is the rate-limiting step in
human carcinogenesis; large organisms such as humans have
evolved a very strong barrier to immortalization via stringent repression
of telomerase activity in adult cells, presumably to suppress tumorigen-
esis. Immortalization is crucial for human carcinoma development notonly for providing additional proliferative capacity, but also because
it makes cells no longer sensitive to oncogene-induced senescence.
However, little is known about the cancer-associated immortalization
processes. Normal cells from small short-lived mammals like mice do
not stringently repress telomerase and lack a significant replicative
senescence barrier. Therefore, unlike human cells, murine cells can
spontaneously immortalize, and cannot model the immortalization
process that occurs during human carcinogenesis. It has been diffi-
cult to efficiently immortalize human epithelial cells with pathologic-
ally relevant agents in order to examine this process. Immortalization
using hTERT precludes examination of the errors responsible for
endogenous telomerase reactivation, while viral oncogenes such as
SV40T or HPVE6E7 are not etiologic agents for breast cancer and
produce many known and unknown effects not seen in breast
cancer cells in vivo.
We achieved efficient non-clonal immortalization of normal human
mammary epithelial cells (HMEC) by directly targeting the two main
senescence barriers encountered by cultured HMEC [1,2]. The first
barrier - stress-associated stasis - results from stresses maintaining an
active Retinoblastoma protein. In human epithelial cells stasis is
enforced by elevated p16INK4A levels, and in murine cells, primarily
by p19ARF (called p14ARF in human cells). Stasis was efficiently bypassed
in HMEC by exposure to shRNA to p16 or overexpressed cyclin D1. Loss
of p16 expression and overexpressed cyclin D1 are commonly seen in
human breast cancers. The replicative senescence barrier was efficiently
bypassed in post-stasis HMEC by MYC transduction; overexpressed
or amplified MYC is seen in the majority of human breast cancers.
Thus just two pathologically relevant oncogenic agents are sufficient
to immortally transform normal finite lifespan HMEC. Further trans-
duction with the mutated ErbB2 oncogene gave anchorage-
independent growth. Crucially, these non-clonal immortalized lines,
including their anchorage-independent derivatives, exhibited normal
karyotypes in early passages. In contrast, all the clonally immortal-
ized lines we have generated (by exposure to chemical carcinogens
or other oncogenic agents) display numerous gross genomic abnor-
malities. These data support our hypothesis that the gross genomic
errors and genomic instability present in human carcinomas may not
be required per se for initiation of transformation, but are needed to
generate the errors that overcome tumor suppressive barriers and
confer malignancy. Additionally, the genomic instability inherently
instigated by telomere dysfunction at replicative senescence may
be mainly responsible for initiating the observed cancer-associated
genomic instability
This method of efficient step-wise HMEC transformation, in the ab-
sence of “passenger” genomic errors, should facilitate examination
of telomerase regulation, as well as the role of putative cancer
drivers, during malignant progression [3]. We also postulate that
the immortalization process –in humans seen only in cells that are
progressing to cancer - could be a valuable therapeutic target.
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Tumor heterogeneity with cells having chromosome 7 (Chr7) copy
number variation (CNV) or EGFR amplification, manifested by double-
minute chromosomes (a.k.a. double minutes or DMs), are commonly
found in malignant gliomas, especially glioblastoma multiforme. The
phenotypic and genetic diversity of tumor subpopulations within a
tumor can lead to therapeutic resistance and tumor recurrence. Un-
derstanding how tumor heterogeneity is maintained and its equilib-
rium optimized in re-forming a tumor, after surgery and front-line
radiation therapy, should help identify interventions targeted to
better combat this deadly disease.
Materials and Methods
From established glioma cell lines and fresh GBM specimens, we
used two culture conditions (serum adherent and neural sphere
cultures) followed by soft-agar colony formation to enrich and
clone two key tumor cell subpopulations that may be responsible
for the resistance to current therapies [1-3]. We carried out studies
on their differential gene/protein expressions, redox and metabolic
states, invasion and proliferation phenotypes, with or without acute
or partitioned irradiation. Florescence in situ hybridization was used
to reveal the proportion of cells with Chr7-CNV and EGFR-DM. Tu-
morigenicities were examined using intracranial xenografts using
the subpopulation-enriched cell line or a mixture of the two syn-
geneic cell lines in various ratios.
Results
We demonstrated that aneuploidy of Chr7 (including one copy of
Chr7 with 7q deletion), or cells with or without EGFR-DM, character-
ized the two key tumor cell subpopulations in malignant gliomas,
by presenting “go” or “grow” molecular signatures and phenotypes
in re-forming orthotropic xenografts [1-3]. The two corresponding
tumor cell subpopulations were designated as the stem-like tumor-
initiating cells (STIC) and the tumor mass-forming cells (TMC). The
lines also differed in redox and metabolic states and in their resist-
ance and response to radiation [2-4]. The heterogeneity of Chr7-
aneuploidy was maintained by Chr7 mis-segregation during prolif-
eration of either STIC or TMC to reach an optimal equilibrium that
benefited overall tumor growth in vitro and in vivo [1]. Chr7 mis-
segregation can be triggered by therapeutic intervention (e.g.
radiotherapy [1]) and alteration in the tumor microenvironment [4].
EGFR-DM heterogeneity, however, was maintained only by cells
with DMs, which had the STIC phenotype, and the ability to form
colonies comprised of cells without DMs, which then carried the
TMC phenotype. Following irradiation, only cells with DMs showed
the ability to switch the respiration machinery from glycolic metab-
olism to oxidative phosphorylation (an anti-Warburg effect), and
the molecular-profile from pro-invasive to pro-angiogenic. Further-
more, radiated cells with DMs altered their extracellular micro-
environment, not only to promote invasiveness of (unirradiated)
surrounding cells with or without DMs, but also to establish an
angiogenic micro-environment supporting re-colonization of the
(heterogeneous) tumor.
Conclusion
Tumor heterogeneity could be maintained by mis-segregation of
tumor-specific chromosomes in response to extracellular environmental
cues. Radio-resistant glioma cells could form a recurrent tumor with the
original tumor heterogeneity by chromosome mis-segregation. New
therapeutic intervention by targeting the extracellular compartment
to control tumor-specific chromosome mis-segregation may suppress
tumor recurrence.Acknowledgements
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Glioblastoma multiforme (GBM) is one of the most aggressive forms of
brain cancer. The tumor is known to be composed of heterogeneous
subpopulations of cells, potentially playing a role in therapeutic resist-
ance. Therefore, an understanding of the tumor heterogeneity is essen-
tial for the development of effective therapies. To further study the
tumor heterogeneity, a culture method was developed to isolate dis-
tinct subpopulations from an established glioma cell line. These sub-
populations include neural stem-like cells and tumor mass cells.
Previous studies have demonstrated that these subpopulations have
different phenotypes, responses to radiotherapy, and levels of oxidative
stress. In this study, fluorescence lifetime imaging microscopy (FLIM) on
the metabolic coenzyme, reduced nicotinamide adenine dinucleotide
(NADH) was performed. NADH is an essential cofactor for oxidative
phosphorylation and glycolysis, therefore the NADH lifetime can be
used as an indicator for metabolic states, with longer lifetimes correlat-
ing to oxidative phosphorylation and shorter lifetimes correlating to
glycolysis. By analyzing the data in the phasor space, the neural stem-
like cells and tumor mass cells can be identified using this label-free,
live cell, imaging technique. Using this method, the effects of cancer
therapies can be evaluated on specific subpopulations of cancer cells
to further our understanding of the role of tumor heterogeneity on
drug resistance.
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